At the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, Joseph Mikhael, MD, MEd, FRCPC, FACP, Translational Genomics Research Institute, City of Hope Cancer Center, Phoenix, Arizona, argued in favor of minimal residual disease (MRD) testing for patients with multiple myeloma, in both a research setting and in clinical practice.
Launch of Myeloma BioBank
The Exciting Launch of Myeloma BioBank: James R. Berenson, MD, Multiple Myeloma, specialist announced in an interview...